



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office,
✉ production.office@frontiersin.org

RECEIVED 02 June 2023
ACCEPTED 02 June 2023
PUBLISHED 12 June 2023

CITATION
Frontiers Production Office (2023),
Erratum: A novel cell-based screen
identifies chemical entities that reverse
the immune-escape phenotype of
metastatic tumours.
Front. Pharmacol. 14:1233717.
doi: 10.3389/fphar.2023.1233717

COPYRIGHT
© 2023 Frontiers Production Office. This
is an open-access article distributed
under the terms of the [Creative
Commons Attribution License \(CC BY\)](#).
The use, distribution or reproduction in
other forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Erratum: A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

antigen processing machinery, curcuphenol, major histocompatibility complex class I, metastatic tumours, natural products, high throughput cell-based assay, drug discovery

An Erratum on

[A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours](#)

by Nohara LL, Ellis SLS, Dreier C, Dada S, Saranchova I, Munro L, Pfeifer CG, Coyle KM, Morrice JR, Shim DJS, Ahn P, De Voogd N, Williams DE, Cheng P, Garrovillas E, Andersen RJ and Jefferies WA (2023). *Front. Pharmacol.* 14:1119607. doi: 10.3389/fphar.2023.1119607

Due to a production error, “Eliana Al Haddad” and “Kyong Bok Choi” were not included as authors in the published article. The corrected **Author contributions** and **Acknowledgments** statements appear below.

Author contributions

Conceived Project: WJ; Designed research: LN, SE, CP, DW, RA, and WJ; Performed research: LN, SE, SD, IS, LM, KC, CD, JM, DS, PA, BE, ND, DW, PC, and EG; Analyzed data: LN, SE, SD, IS, LM, CP, KC, CD, JM, DS, PA, BE, TM, ND, DW, PC, NL, EG, RA, and WJ; Wrote the paper: LN, SE, RA, and WJ; Edited the paper: LN, SE, CP, TM, DW, NL, EG, RA, and WJ.

Acknowledgments

We would like to thank Professor Michel Roberge for critical discussion and access to the Cellomics Screening System.

The publisher apologizes for these mistakes. The original version of this article has been updated.